Abstract: The present invention provides a method for enhancing the secretion of GLP-1 of the intestinal endocrine L-cells using a bitter compound, wherein the bitter compound is a cucurbitane-triterpenoid or allyl isothiocyanate. The bitter compound can regulate the secretion of GLP-1, thus is potentially reliable for the development of medicament or healthy victual.

Abstract: The present invention provides a composition for the regulation of Liver X Receptor (LXR) in a cell, and the composition comprises fucoxanthin and its metabolite, fucoxanthinol. The composition of the present invention regulates the transactivation activity of LXR in cell, and antagonizes the transactivation activity of LXR? and/or LXR? induced by LXR agonists. In other aspects, the present invention also provides a method of regulating a liver X receptor. The composition for the regulation of liver X receptor and the application thereof according to the present invention can regulate the transactivation activity of LXR in cell, and can further be used as alternatives for LXR agonist or antagonist, or supplements, for enhancing LXR-related symptoms.

Abstract: The present invention provides a method for enhancing the secretion of GLP-1 of the intestinal endocrine L-cells using a bitter compound, wherein the bitter compound is a cucurbitane-triterpenoid or allyl isothiocyanate. The bitter compound can regulate the secretion of GLP-1, thus is potentially reliable for the development of medicament or healthy victual.

Abstract: Disclosed is a cucurbitane-triterpenoid compound for activating estrogen receptor activity, and a pharmaceutical composition, use and preparation method thereof. The cucurbitane-triterpenoid compound is presented as formula (I): wherein a single bond or a double bond is formed between C5 and C10, and a single bond or a double bond is fromed between C8 and C9; when a single bond is formed between C5 and C10, the R1 is oxygen; while a single bond is formed between C8 and C9, R2 is carbonyl group (—C?O), methyl hydroxyl group (—CH(OH)), methyl ketone or methyl dimethoxy group (—CH(OCH3)2); and wherein while R1 is oxygen (—O—) and R2 is carbonyl group (—C?O) or methyl hydroxyl group (—CH(OH)), a single bond is formed between R1 (—O—) and C19 of R2 such that R1 and R2 are formed tetrahydro-2H-pyran-2-one or hemiacetal ring.

Abstract: The present invention provides a mitochondria regulator composition, which comprises a wild bitter gourd extract. The mitochondria regulator composition can regulate the function of mitochondria in a cell, and further regulate the efficiency of adaptive thermogenesis and energy expenditure in a cell.

Abstract: The present invention provides a mitochondria regulator composition, which comprises a wild bitter gourd extract. The mitochondria regulator composition can regulate the function of mitochondria in a cell, and further regulate the efficiency of adaptive thermogenesis and energy expenditure in a cell.

Abstract: Disclosed is a method for alleviating allergic asthma by using a bitter melon composition. The bitter melon composition comprises at least an effective amount of conjugated linolenic acid (CLN), wherein the bitter melon composition is administered to a subject suffering from allergic asthma to alleviate its symptoms. In the future, the bitter melon composition can be developed to as a health food, so as to prevent asthma, or alleviate the various symptoms of allergic asthma, such as airway hyperresponsiveness (AHR), airway inflammation, infiltration of inflammatory cell in lung tissue, or high level of serum IgE.

Abstract: Disclosed is a cucurbitane-triterpenoid compound for activating estrogen receptor activity, and a pharmaceutical composition, use and preparation method thereof. The cucurbitane-triterpenoid compound is presented as formula (I): wherein a single bond or a double bond is formed between C5 and C10, and a single bond or a double bond is fromed between C8 and C9; when a single bond is formed between C5 and C10, the R1 is oxygen; while a single bond is formed between C8 and C9, R2 is carbonyl group (—C?O), methyl hydroxyl group (—CH(OH)), methyl ketone or methyl dimethoxy group (—CH(OCH3)2); and wherein while R1 is oxygen (—O—) and R2 is carbonyl group (—C?O) or methyl hydroxyl group (—CH(OH)), a single bond is formed between R1 (—O—) and C19 of R2 such that R1 and R2 are formed tetrahydro-2H-pyran-2-one or hemiacetal ring.

Abstract: The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ER? and simultaneously express high estrogenic activity, and also can be applied as medical or food compositions to improve estrogen deficiency-related symptoms.

Abstract: The present invention provides a process for producing a composition containing a high concentration of aglucone isoflavones, which comprises adding glucone isoflavones to the fermentation of microorganisms which are generally recognized as safe, and can express or produce ?-glycosidase on a soy-based substrate. The present invention also provides a composition containing a high concentration of aglucone isoflavones produced in accordance with the process of the invention.

Abstract: The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ER? and simultaneously express high estrogenic activity, and also can be applied as medical or food compositions to improve estrogen deficiency-related symptoms.

Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.